Immune Network Research Ltd -
Research progress; re-elections
Immune Network Research Ltd IMMShares issued 19,970,4521998-06-30 close $0.17Thursday Jul 2 1998VANCOUVER, B.C. (July 2, 1998) - Victor Jones, President, reviewed corporate and research developments for the Company at the 1998 Annual General Meeting. Preliminary indications from the Phase II macaque study of the Company's proprietary monoclonal antibody, 1F7, support corporate plans for both continued research and preparation for a limited initial clinical trial in humans (Phase I). The macaque is a preferred research model for HIV disease in humans and the current study is scheduled to continue through September. The proposed new drug appears to act as an adjuvant to diversify and strengthen the immune system response in macaques infected with SHIV. Shareholders affirmed the present Board of Directors, re-electing Dal Brynelsen, Robert Gayton, Dr. Michael Grant, Victor Jones, Richard Richards, and Dr. Donald Rix. Officers appointed immediately following the shareholders' meeting were: Victor Jones, President; Jennifer Nestoruk, Corporate Secretary; Dr. Michael Grant, Vice-President, Research; and Alex Rainard, Vice-President, Corporate Development. The life sciences company is focused on monoclonal antibody therapeutics for diseases of the immune system.
Victor J.E. Jones
President
For additional information please contact:
Tel. (604) 689-3923
Fax. (604) 684-5854
www.stockgroup.com/imm.html
THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE
Immune Network Research Ltd.
900 - 475 Howe Street
Vancouver, B.C., Canada V6C 2B3
Tel. (604) 689-3923
Fax. (604) 684-5854
www.stockgroup.com/imm.html
(c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com
old url (better for printing) |
